Generic Medicine Info
Should be taken with food. Take after meals or a light snack.
History of toxicity to gold compounds including necrotizing enterocolitis, pulmonary fibrosis, severe chronic dermatitis (e.g. exfoliative dermatitis, severe urticaria/eczema), severe haematological disorder (e.g. bone marrow aplasia, thrombocytopenia, leucopenia, aplastic anaemia). Concomitant use w/ clozapine, antimalarial agents, penicillamine, and immunosuppressive agents. Lactation.
Special Precautions
Patient w/ inflammatory bowel disease, history of bone marrow depression, acute porphyria, DM, HTN, CHF. Patient undergoing radiotherapy. Hepatic (e.g. hepatocellular disease) and renal impairment (e.g. progressive renal failure). Pregnancy. Monitoring Parameters Monitor CBC w/ differential, platelet count, and urinalysis at baseline and during therapy. Monitor hepatic and renal function.
Adverse Reactions
Nausea w/ or w/o vomiting, abdominal pain, loose stools/diarrhoea, anorexia, flatulence, dyspepsia, dysgeusia, constipation; rash, pruritus, hair loss, urticaria, photosensitivity; stomatitis, conjunctivitis, glossitis; anaemia, leucopenia, granulocytopenia, thrombocytopenia, eosinophilia; haematuria, proteinuria, increased BUN and serum creatinine; elevated liver enzymes.
Drug Interactions
Altered absorption and increased toxicity w/ drugs affecting GI motility (e.g. prokinetics, loperamide, senna). May cause blood dyscrasias w/ phenylbutazone, oxyphenbutazone, levamisole, high-dose corticosteroids. May increase risk of vasomotor reaction w/ ACE inhibitors. May cause renal impairment or proteinuria w/ aminoglycosides, amphotericin B, penicillins, phenytoin, sulfonamides, NSAIDs, aciclovir. May increase plasma concentration of phenytoin.
ATC Classification
M01CB03 - auranofin ; Belongs to the class of gold preparations of antirheumatic agents.
Disclaimer: This information is independently developed by CIMS based on auranofin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in